ArticlePsychiatric services (Washington, D.C.)2013
How quickly do physicians adopt new drugs? The case of second-generation antipsychotics.
Article in Psychiatric services (Washington, D.C.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.BMC health services research · 2021Pooled it
- Factors affecting the uptake of new medicines: a systematic literature review.BMC health services research · 2014Pooled it
- Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?RMD open · 2024Article
- Latent Class Analysis of Prescribing Behavior of Primary Care Physicians in the Veterans Health Administration.Journal of general internal medicine · 2022Article
- A Bayesian hierarchical model for characterizing the diffusion of new antipsychotic drugs.Biometrics · 2021Article
- Do we need to change our treatment approach to schizophrenia during the COVID-19 pandemic?International journal of clinical practice · 2021Article
- The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea.BMC public health · 2020Article
- Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.BMC health services research · 2019Article
- Patient Characteristics Associated with Receipt of Prescription Weight-Management Medications Among Veterans Participating in MOVE!Obesity (Silver Spring, Md.) · 2019Article
- Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study.British journal of clinical pharmacology · 2018Article
- Association of Healthcare Plan with atrial fibrillation prescription patterns.Clinical cardiology · 2018Article
- Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules.Biometrics · 2018Article
- Patterns and predictors of physician adoption of new cardiovascular drugs.Healthcare (Amsterdam, Netherlands) · 2018Article
- Determinants of new drugs prescription in the Swiss healthcare market.BMC health services research · 2018Article
- A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics.CNS drugs · 2017Article
- New chronic disease medication prescribing by nurse practitioners, physician assistants, and primary care physicians: a cohort study.BMC health services research · 2016Article
- Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory Models.Medical care · 2016Article
- Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures.The journal of mental health policy and economics · 2016Article
- Changing patterns of alpha agonist medication use in children and adolescents 2009-2011.Journal of child and adolescent psychopharmacology · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe authors examined physician adoption of second-generation antipsychotic medications and identified physician-level factors associated with early adoption.
methodsThe authors estimated Cox proportional-hazards models of time to adoption of nine second-generation antipsychotics by 30,369 physicians who prescribed antipsychotics between 1996 and 2008, when the drugs were first introduced, and analyzed the total number of agents prescribed during that time. The models were adjusted for physicians' specialty, demographic characteristics, education and training, practice setting, and prescribing volume. Data were from IMS Xponent, which captures over 70% of all prescriptions filled in the United States, and the American Medical Association Physician Masterfile.
resultsOn average, physicians waited two or more years before prescribing new second-generation antipsychotics, but there was substantial heterogeneity across products in time to adoption. General practitioners were much slower than psychiatrists to adopt second-generation antipsychotics (hazard ratios (HRs) range .10-.35), and solo practitioners were slower than group practitioners to adopt most products (HR range .77-.89). Physicians with the highest antipsychotic-prescribing volume adopted second-generation antipsychotics much faster than physicians with the lowest volume (HR range .15-.39). Psychiatrists tended to prescribe a broader set of antipsychotics (median=6) than general practitioners and neurologists (median=2) and pediatricians (median=1).
conclusionsAs policy makers search for ways to control rapid health spending growth, understanding the factors that influence physician adoption of new medications will be crucial in the efforts to maximize the value of care received by individuals with mental disorders as well as to improve medication safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.